Biotech Company Adcendo Announces Series A Extension At €82 Million
By Annie Baker ● Apr 11, 2023
Adcendo ApS - a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need - announced the successful completion of a Series A extension financing, raising a further €31 million, following the €51 million Series A financing in April 2021.